U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06863584) titled 'SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial' on March 03.
Brief Summary: Solitary Plasmacytoma (SP) is a rare malignant plasma cell tumor, including Solitary Bone Plasmacytoma (SBP) and Solitary Extramedullary Plasmacytoma (SEP). Radiotherapy is the preferred treatment for SP. Although the local response rate of SP after radiotherapy is as high as 86%, 55% of patients will experience disease progression within 5 years.
Stereotactic Body Radiation Therapy (SBRT), as a new technology for "precision radiotherapy," delivers a higher dose of radiation to the tumor site through a few short treatment sessions while ma...